These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 31209398)
21. Pharmacological rhythm versus rate control in patients with atrial fibrillation and heart failure: the CASTLE-AF trial. Zhao Y; Krupadev V; Dagher L; Mahnkopf C; Sohns C; Sehner S; Suling A; Sanders P; Boersma L; Schunkert H; Wegscheider K; Brachmann J; Marrouche NF J Interv Card Electrophysiol; 2021 Sep; 61(3):609-615. PubMed ID: 32888121 [TBL] [Abstract][Full Text] [Related]
22. Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial. Piccini JP; Abraham WT; Dufton C; Carroll IA; Healey JS; van Veldhuisen DJ; Sauer WH; Anand IS; White M; Wilton SB; Aleong R; Rienstra M; Krueger SK; Ayala-Paredes F; Khaykin Y; Merkely B; Miloradović V; Wranicz JK; Ilkhanoff L; Ziegler PD; Davis G; Emery LL; Marshall D; Kao DP; Bristow MR; Connolly SJ; JACC Heart Fail; 2019 Jul; 7(7):586-598. PubMed ID: 31042551 [TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of resting heart rate in atrial fibrillation patients with heart failure with reduced ejection fraction. Suzuki S; Motoki H; Kanzaki Y; Maruyama T; Hashizume N; Kozuka A; Yahikozawa K; Kuwahara K Heart Vessels; 2020 Aug; 35(8):1109-1115. PubMed ID: 32144498 [TBL] [Abstract][Full Text] [Related]
24. Prescription Rates and Prognostic Implications of Optimally Targeted Guideline-Directed Medical Treatment in Heart Failure and Atrial Fibrillation: Insights From The MISOAC-AF Trial. Moysidis DV; Kartas A; Samaras A; Papazoglou AS; Patsiou V; Bekiaridou A; Baroutidou A; Tsagkaris C; Karagiannidis E; Daios S; Anastasiou V; Tsalikakis D; Efthimiadis G; Ziakas A; Tzikas A; Giannakoulas G J Cardiovasc Pharmacol; 2023 Mar; 81(3):203-211. PubMed ID: 36626410 [TBL] [Abstract][Full Text] [Related]
25. Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. Mentz RJ; Chung MJ; Gheorghiade M; Pang PS; Kwasny MJ; Ambrosy AP; Vaduganathan M; O'Connor CM; Swedberg K; Zannad F; Konstam MA; Maggioni AP Am Heart J; 2012 Dec; 164(6):884-92.e2. PubMed ID: 23194489 [TBL] [Abstract][Full Text] [Related]
26. Guideline-directed therapy at discharge in patients with heart failure and atrial fibrillation. Ahn MS; Yoo BS; Yoon J; Lee SH; Kim JY; Ahn SG; Youn YJ; Lee JW; Son JW; Kim HS; Kang DR; Cho HJ; Lee HY; Jeon ES; Kang SM; Choi DJ; Cho MC Heart; 2020 Feb; 106(4):292-298. PubMed ID: 31492703 [TBL] [Abstract][Full Text] [Related]
27. Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. Mogensen UM; Jhund PS; Abraham WT; Desai AS; Dickstein K; Packer M; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Køber L; McMurray JJV; J Am Coll Cardiol; 2017 Nov; 70(20):2490-2500. PubMed ID: 29145948 [TBL] [Abstract][Full Text] [Related]
28. Impact of digoxin on risk of death in heart failure patients treated with b-blockers. Results from Polish part of ESC Heart Failure Long-Term Registry. Migaj J; Kałużna-Oleksy M; Nessler J; Opolski G; Crespo-Leiro MG; Maggioni AP; Grajek S; Ponikowski P; Drożdż J; Straburzyńska-Migaj E Kardiol Pol; 2018; 76(7):1064-1072. PubMed ID: 29476617 [TBL] [Abstract][Full Text] [Related]
29. Comparison of beta blocker and digoxin alone and in combination for management of patients with atrial fibrillation and heart failure. Fauchier L; Grimard C; Pierre B; Nonin E; Gorin L; Rauzy B; Cosnay P; Babuty D; Charbonnier B Am J Cardiol; 2009 Jan; 103(2):248-54. PubMed ID: 19121446 [TBL] [Abstract][Full Text] [Related]
30. Prognostic Significance of Heart Rate and Beta-Blocker Use in Sinus Rhythm in Patients with Heart Failure and Preserved Ejection Fraction. Li S; Li X High Blood Press Cardiovasc Prev; 2019 Oct; 26(5):405-411. PubMed ID: 31625118 [TBL] [Abstract][Full Text] [Related]
31. Differences in the Effects of Beta-Blockers Depending on Heart Rate at Discharge in Patients With Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation. Kim YI; Ahn MS; Yoo BS; Kim JY; Son JW; Park YJ; Kim SH; Kang DR; Lee HY; Kang SM; Cho MC Int J Heart Fail; 2024 Jul; 6(3):119-126. PubMed ID: 39081646 [TBL] [Abstract][Full Text] [Related]
32. Clinical characteristics and predictors of one-year outcome of heart failure patients with atrial fibrillation compared to heart failure patients in sinus rhythm. Ozierański K; Kapłon-Cieślicka A; Peller M; Tymińska A; Balsam P; Galas M; Marchel M; Crespo-Leiro M; Maggioni AP; Drożdż J; Opolski G Kardiol Pol; 2016; 74(3):251-61. PubMed ID: 26365943 [TBL] [Abstract][Full Text] [Related]
33. Beta-blockers and 1-year clinical outcomes in hospitalized heart failure patients with atrial fibrillation. Xing FW; Zhang LH; Zhang HB; Bai XK; Hu DL; Zheng X; Li J J Geriatr Cardiol; 2021 Sep; 18(9):728-738. PubMed ID: 34659379 [TBL] [Abstract][Full Text] [Related]
34. β-blockers and risk of all-cause mortality in patients with chronic heart failure and atrial fibrillation-a meta-analysis. Xu T; Huang Y; Zhou H; Bai Y; Huang X; Hu Y; Xu D; Zhang Y; Zhang J BMC Cardiovasc Disord; 2019 Jun; 19(1):135. PubMed ID: 31159740 [TBL] [Abstract][Full Text] [Related]
35. Association between resting heart rate, chronotropic index, and long-term outcomes in patients with heart failure receiving β-blocker therapy: data from the HF-ACTION trial. Dobre D; Zannad F; Keteyian SJ; Stevens SR; Rossignol P; Kitzman DW; Landzberg J; Howlett J; Kraus WE; Ellis SJ Eur Heart J; 2013 Aug; 34(29):2271-80. PubMed ID: 23315907 [TBL] [Abstract][Full Text] [Related]
36. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Nasr IA; Bouzamondo A; Hulot JS; Dubourg O; Le Heuzey JY; Lechat P Eur Heart J; 2007 Feb; 28(4):457-62. PubMed ID: 17289748 [TBL] [Abstract][Full Text] [Related]
37. Ventricular rate in atrial fibrillation and the risk of heart failure and death. Westergaard LM; Alhakak A; Rørth R; Fosbøl EL; Kristensen SL; Svendsen JH; Graff C; Nielsen JB; Gislason GH; Køber L; Torp-Pedersen C; Lee CJY; Weeke PE Europace; 2023 May; 25(5):. PubMed ID: 37083042 [TBL] [Abstract][Full Text] [Related]
38. Intravenous metoprolol versus diltiazem for atrial fibrillation with concomitant heart failure. Compagner CT; Wysocki CR; Reich EK; Zimmerman LH; Holzhausen JM Am J Emerg Med; 2022 Dec; 62():49-54. PubMed ID: 36252310 [TBL] [Abstract][Full Text] [Related]
39. Impact of initial heart failure emergence on clinical outcomes of atrial fibrillation patients in the AFFIRM trial. Slee A; Saksena S Am Heart J; 2020 Feb; 220():1-11. PubMed ID: 31756389 [TBL] [Abstract][Full Text] [Related]
40. Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial. Abualnaja S; Podder M; Hernandez AF; McMurray JJ; Starling RC; O'Connor CM; Califf RM; Armstrong PW; Ezekowitz JA J Am Heart Assoc; 2015 Aug; 4(8):e002092. PubMed ID: 26304935 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]